

Figure 1

Anti-CD89 14.1 VH

Q V Q L V E S G G G V V Q P G R S L
CAG GTG CAA CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG TCC CTG

CDR1
~~~~~  
R L S C A A S G F T F S S Y V L H W  
AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGT TAT GTT CTG CAC TGG

CDR2  
~~~~~  
V R Q A P G K G L D W V A V I S D D
GTC CGC CAG GCT CCA GGC AAG GGG CTG GAT TGG GTG GCA GTG ATA TCA GAT GAT

CDR2
~~~~~  
G R N K Y F A D S V K G R F T I S R  
GGA AGG AAT AAA TAC TTC GCA GAC TCC GTG AAG GGC CGA TTC ACC ATC TCC AGA

D N S K N T L Y L Q M N S L R A E D  
GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA GCT GAG GAC

CDR3  
~~~~~  
T A V Y Y C V R E G Y S G S W F D Y
ACG GCT GTG TAT TAC TGT GTG AGA GAA GGG TAT AGC GGC AGC TGG TTT GAC TAC

W G Q G T L V T V S S
TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA

10073644-02-102

Figure 2

Anti-CD89 14.1 VK

```
A  I  Q  L  T  Q  S  P  S  S  L  S  A  S  V  G  D  R
GCC ATC CAG TTG ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA GAC AGA

                                CDR1
~ ~ ~ ~ ~
V  T  I  T  C  R  A  S  Q  G  I  S  S  A  L  A  W  Y
GTC ACC ATC ACT TGC CGG GCA AGT CAG GGC ATT AGC AGT GCT TTA GCC TGG TAT

                                CDR2
~ ~ ~ ~ ~
Q  Q  K  P  G  K  A  P  K  L  L  I  Y  G  A  S  S  L
CAG CAG AAA CCA GGG AAA GCT CCT AAG CTC CTG ATC TAT GGT GCC TCC AGT TTG

~ ~ ~ ~ ~
E  G  G  V  P  S  R  F  S  G  S  G  S  G  T  D  F  T
GAA GGT GGG GTC CCA TCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC ACT

                                CDR3
~ ~ ~ ~ ~
L  T  I  S  S  L  Q  P  E  D  F  A  T  Y  Y  C  Q  Q
CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT GCA ACT TAT TAC TGT CAA CAG

~ ~ ~ ~ ~
F  N  S  Y  P  F  T  F  G  P  G  T  K  V  D  I  K
TTT AAT AGT TAC CCA TTC ACT TTC GGC CCT GGG ACC AAA GTG GAT ATC AAA
```

20120419E201

Figure 3

Anti-CD89 8.2 VH

Q V Q L V E S G G G V V Q P G R S L
CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG TCC CTG

CDR1

R L S C A A S G F T F S S Y A M H W
AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT GCT ATG CAC TGG

CDR2

V R Q A P G K G L E W V A V I S Y D
GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG GCA GTT ATA TCA TAT GAT

CDR2

G R N K D Y A D S V K G R F T I S R
GGA AGA AAT AAA GAC TAC GCA GAC TCC GTG AAG GGC CGA TTC ACC ATC TCC AGA

D N S K N T L Y L Q M N S L R A E D
GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA GCT GAG GAC

CDR3

T A V H Y C A R L D W G Y D A F D I
ACG GCT GTG CAT TAC TGT GCG AGG CTT GAC TGG GGA TAT GAT GCT TTT GAT ATC

W G Q G T M V T V S S
TGG GGC CAA GGG ACA ATG GTC ACC GTC TCT TCA

20130414 14:36:44

Figure 4

Anti-CD89 8.2 VK

E I V L T Q S P G T L S L S P G E R
GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT TTG TCT CCA GGG GAA AGA

CDR1

A T L S C R A S Q S V S S S Y L A W
GCC ACC CTC TCC TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA GCC TGG

CDR2

Y Q Q K P G Q A P R L L I Y G A S S
TAC CAG CAG AAG CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT GCA TCC AGC

CDR2

R A T G I P D R F S G S G S G T D F
AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC

CDR3

T L T I S R L E P E D F A V Y Y C Q
ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT GCA GTG TAT TAC TGT CAG

CDR3

Q Y G S S P P Y T F G Q G T K L E I
CAG TAT GGT AGC TCA CCT CCG TAC ACT TTT GGC CAG GGG ACC AAG CTG GAG ATC

K
AAA

10073644-021102